Deckers Outdoor Corp vs Cassava Sciences Inc — how do they compare? Deckers Outdoor Corp trades at $106.98 (market cap $14.97B), while Cassava Sciences Inc trades at $1.09 (market cap $56.04M). The key difference: Deckers Outdoor Corp is far larger — about 267.1× Cassava Sciences Inc's market cap, and Deckers Outdoor Corp is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| DECK | FLNA | |
|---|---|---|
Market Cap | $14.97B | $56.04M |
Sector | Consumer Cyclical | Health |
52-Week High | $123.91 | $4.64 |
52-Week Low | $79.54 | $1.09 |
Enterprise Value | $13.44B | -$30.54M |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
FLNA trades at $1.15, down 2.54% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company continues to report losses, with a net income of -$90.97M in 2025 and negative cash flow, though it has beaten EPS estimates for the last three quarters. Recent news highlights ongoing development in its TSC-related epilepsy therapies.
Despite consistent earnings beats, FLNA's negative profitability and cash burn pose significant risks. Analyst sentiment is positive with a 66.7% buy rating, but the stock's outlook depends heavily on clinical success and future funding. Investors should weigh the high-risk, high-reward nature of this biotech play.
Trailing returns across standard periods
Latest headlines on both assets
Deckers Outdoor Corp designs and sells casual and performance footwear, apparel, and accessories. Primary brands include UGG, Teva, and Sanuk. The company distributes Most of its products through its wholesale business, but it also has a substantial direct-to-consumer business with its company-owned retail stores and websites. Most sales are in the United States, although the company also has retail stores and distributors throughout Europe, Asia, Canada, and Latin America. Deckers sources its products from independent manufacturers primarily in Asia.
Read more on DECK →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →